Cassava Sciences, Inc. (SAVA)
| Market Cap | 3.11B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -8.71M |
| Shares Out | 37.72M |
| EPS (ttm) | -0.30 |
| PE Ratio | n/a |
| Forward PE | 94.34 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | June 22 |
| Last Price | $77.63 |
| Previous Close | $89.72 |
| Change ($) | -12.09 |
| Change (%) | -13.48% |
| Day's Open | 88.43 |
| Day's Range | 72.48 - 89.15 |
| Day's Volume | 6,482,255 |
| 52-Week Range | 2.65 - 117.54 |
Cassava Sciences' (SAVA) completes enrollment in its open-label study on simufilam. It plans to begin two pivotal phase III studies on simufilam in the second half of 2021.
Cassava Sciences (SAVA) has moved higher as of late, but there could definitely be trouble on the horizon for this company
The stock price of Cassava Sciences, a clinical stage biotechnology company focused on treatment for Alzheimer's disease, has seen a massive 66% rise over the last twenty-one trading days, while it is ...
Investors applauded the company's update on its clinical programs.
Selection of Premier Research as CRO Marks Significant Milestone Toward Initiation of Phase 3 Program of Simufilam in Alzheimer's Disease Selection of Premier Research as CRO Marks Significant Milestone...
Cassava Sciences Inc (NASDAQ:SAVA) shares are trading higher by 11.2% at $88.50 after the company highlighted clinical development progress and provided guidance on upcoming data releases for simufilam,...
Cassava Sciences Inc (NASDAQ: SAVA) has announced a mid-year update highlighting clinical development progress and providing guidance on upcoming data releases for simufilam and SavaDx. Simufilam is Ca...
AUSTIN, Texas, June 21, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer's disease, today announced a mid-year update that highlights clinical...
Cassava Sciences, Inc. (SAVA) closed at $79.65 in the latest trading session, marking a +1.34% move from the prior day.
AUSTIN, Texas, June 17, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer's disease, today announced that it has been invited to...
New approaches to treating Alzheimer's could mean even bigger gains in the future.
- Mr. Barry To Contribute Additional Board-level Perspective Around Growth, Governance, Sustainability and Societal Goals –
Data doesn't lie. These companies have the potential to quickly steal the spotlight.
FDA approves Biogen's (BIIB) Alzheimer's disease ("AD") drug, Aduhelm (aducanumab). Stocks of Eli Lilly (LLY), Cassava Sciences (SAVA) and Annovis Bio (ANVS) rise as they also have AD candidates in thei...
Thanks to key funding, its Alzheimer's drug is on track even after Biogen's historic approval.
Investors need to pay close attention to Cassava Sciences (SAVA) stock based on the movements in the options market lately.
- Virtual Panel to be Held on Wednesday, May 26 th , 11:00am Eastern Time -
Caladrius Biosciences Inc (NASDAQ: CLBS) has received $1.4 million in non-dilutive funding as an approved participant of the Technology Business Tax Certificate Transfer Program sponsored by the New Jer...
- Research Grant Will Support Clinical Readiness Activities in Support of Upcoming Phase 3 Program with Simufilam - - Research Grant Will Support Clinical Readiness Activities in Support of Upcoming Pha...
It signals a big push toward curing a neurological disease with a massive market.
- Randomized, Controlled Study is Designed to Evaluate Cognition in Patients Who Continue Versus Discontinue Simufilam Over Six Months –
Fireside Chat on Wednesday, April 28th at 2:30PM Eastern Fireside Chat on Wednesday, April 28th at 2:30PM Eastern
Cassava Sciences Invited by the NIH to Participate in Sachs 4th Annual Neuroscience Innovation Forum
AUSTIN, Texas, April 26, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer's disease, today announced that it has been invited t...
While Biogen rides a big-cap rollercoaster, a few small players are creating better trading opps.
- 9 Month Interim Analysis of Open-label Study to be Presented at a Major Scientific Conference in July 2021 as an Oral Presentation -
In the latest trading session, Cassava Sciences, Inc. (SAVA) closed at $34.85, marking a -0.68% move from the previous day.
These high-flying stocks may soon reverse course.
Being able to scout for future growth potential is a crucial pillar of investing success.
These stocks have been unstoppable since late December -- but will they stay that way?
Is (SAVA) Outperforming Other Medical Stocks This Year?
AUSTIN, Texas, March 23, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer's disease, today announced financial results for the ...
A potential new treatment for Alzheimer's disease could be worth billions.
The stock price of Cassava Sciences, a clinical stage biotechnology company focused on treatment for Alzheimers, has seen a 7% rise over the last ten trading days, while it is up 1% over the last five t...
Here's why these attention-grabbing stocks could be toxic to your portfolio.
An analyst expects shares to more than double over the next 12 months.
One of the most common questions traders have about stocks is “Why Is It Moving?” That's why Benzinga created the Why Is It Moving, or WIIM, feature in Benzinga Pro.
Though the U.S. economy is far from pre-pandemic levels, it has shown solid improvement. Meanwhile, the stock market has strongly bounced back and reached new milestones.
Cassava Sciences (SAVA) is progressing well with development of its Alzheimer's disease candidate, simufilam.
AUSTIN, Texas, March 09, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company developing product candidates for Alzheimer's disease, today announced it ...
Is (SAVA) Outperforming Other Medical Stocks This Year?
Promising results for the company's lead Alzheimer's drug have made Cassava one of 2021's most exciting stocks.
AUSTIN, Texas, March 08, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company developing product candidates for Alzheimer's disease, has been invited to...
Its promising potential treatment for Alzheimer's disease is going to enter phase 3 trials later this year.
SAVA stock has plenty of long-term potential after the company posted clinical results from its Alzheimer's disease study. The post Why Cassava Sciences Has Tremendous Upside Potential appeared first on...
Cassava Sciences will likely be a winner in the fight against Alzheimer's. If successful, SAVA stock is worth significantly more.
Investors need to pay close attention to Cassava Sciences (SAVA) stock based on the movements in the options market lately.
Cassava Sciences, Inc. (SAVA) closed the most recent trading day at $52.37, moving -1.23% from the previous trading session.
Cassava Sciences (SAVA) will provide updates on its pipelinewhen it reports fourth-quarter 2020 results.
AUSTIN, Texas, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company developing product candidates for Alzheimer's disease, has been invited to ...
About SAVA
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, T... [Read more...]
| Industry Biotechnology | Founded 1998 |
| CEO Remi Barbier | Employees 11 |
| Stock Exchange NASDAQ | Ticker Symbol SAVA |
Analyst Forecasts
According to 3 analysts, the average rating for SAVA stock is "Buy." The 12-month stock price forecast is 77.80, which is an increase of 0.22% from the latest price.